Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F22%3AN0000044" target="_blank" >RIV/00064190:_____/22:N0000044 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10447805 RIV/00064190:_____/23:10000982
Result on the web
<a href="https://doi.org/10.1111/all.15513" target="_blank" >https://doi.org/10.1111/all.15513</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/all.15513" target="_blank" >10.1111/all.15513</a>

Result language
angličtina
Original language name
Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma
Original language description
Asthma is a heterogeneous disease, as reflected by differences in age of onset, severity, treatment response and inflammatory profile. Matrix metalloprotease (MMP)-12 has been associated with inflammation in various subtypes of asthma.1 In allergic asthma, MMP-12 activity has been implicated in the accumulation of neutrophils and eosinophils, in regulating macrophage functions and in the development of airway hyperresponsiveness (AHR).1 To date, the underlying mechanisms by which MMP-12 may drive asthma pathophysiology have not been defined, nor has inhibition of MMP-12 as a targeted therapy for asthma been assessed in humans. FP-025 is a novel, potent, and highly selective non-hydroxamate inhibitor of MMP-12 with 90-fold selectivity over the closest family member (MMP-2) and two to three orders of magnitude over the seven other MMP family members.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30225 - Allergy

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)